SCHEMBL5149015

SCHEMBL5149015

COC(=O)c1nc(-c2ccc(=O)n(C(C)C)n2)c(-c2ccccc2)nc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 2/20 0.38
MAPT P10636 5/20 0.38
KDM4E B2RXH2 2/20 0.38
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
AKT1 P31749 2/20 0.36
AKT2 P31751 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150959 0.83 FGFR1 (0.39) TP53SMN1; SMN2POLB
SCHEMBL5149011 0.80 CNR1 (0.41) TP53ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5149199 0.80 USP8 (0.50) TP53ALDH1A1LMNAKDM4E
SCHEMBL5152639 0.78 PLAU (0.40) TP53KDM4EPOLB
SCHEMBL5149097 0.78 RET (0.41) TP53POLB
SCHEMBL5149017 0.78 TP53 (0.43) TP53POLB
SCHEMBL5152629 0.78 RET (0.41) TP53POLB
SCHEMBL6539015 0.77 KDM5A (0.42) TP53ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5148007 0.77 MAPT (0.45) TP53ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5149209 0.77 MAPT (0.45) TP53ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 TP53 2221/4885ALDH1A1 748/4885SMN1; SMN2 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.